Review of TA243; Rituximab for the first-line treatment of stage III-IV follicular lymphoma, and TA226; Rituximab for first line maintenance treatment of follicular non-Hodgkin's lymphoma

The Institute was proposing that both pieces of guidance should be moved to the ‘static guidance list’.

During consultation, the majority of comments received by the Institute agreed with the proposal put forward.  After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal.

Consequently, both TA243 and TA226 will be moved to the ‘static guidance list’.  Topics on the static list can be considered for review if any new evidence becomes available that is likely to lead to a change in the existing recommendations.

August 2014

Attachments